<DOC>
	<DOCNO>NCT00737464</DOCNO>
	<brief_summary>This single arm study evaluate maintenance hemoglobin level , safety tolerability once-monthly intravenous administration Mircera dialysis patient chronic renal anemia . Patients receive intravenous Mircera ( 120 , 200 360 microgram ) every four week depend previous dose epoetin alfa administer week precede first study drug administration . Patients treat 12 week follow 2 week last treatment visit . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Once Monthly Intravenous Mircera Maintenance Treatment Dialysis Patients With Chronic Renal Anemia .</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>male female patient , &gt; =18 year age ; chronic renal anemia ; Hb concentration 10.5g/dL 12.5g/dL ; continuous intravenous maintenance therapy epoetin alfa dose interval previous 2 month . blood transfusion within previous 2 month ; poorly control hypertension ; significant acute chronic bleeding ; active malignant disease ; congestive heart failure ( NYHA Class IV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>